<?xml version="1.0" encoding="UTF-8"?>
<p>Even though the prevalence of COVID‚Äê19 arrhythmogenic effects has yet not been reported, close cardiovascular surveillance is advisable, particularly in patients with more severe presentation and in those with increased baseline risk due to previous cardiac comorbidities. Since many medications are being used empirically to treat the infection and/or symptoms, there is a need to increase awareness to possible drug interactions and close monitoring in atrioventricular conduction and QT interval.</p>
